Safety of fosphenytoin sodium

American Journal of Health-System Pharmacy

Volumn 53, Issue 22, 1996, Pages 2707-2712

  Fierro, Lesley S ^a   Savulich, Donna H ^a   Benezra, Diane A ^a  

^a PFIZER INC   (United States)

Author keywords

Anticonvulsants; Blood levels; Dosage; Drug administration routes; Drug comparisons; Drug interactions; Drugs; Fosphenytoin sodium; Injections; Metabolism; Phenytoin sodium; Status epilepticus; Toxicity

Indexed keywords

FOSPHENYTOIN SODIUM; PHENYTOIN; PLACEBO;

CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONVULSION; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG SAFETY; DRUG SOLUBILITY; DRUG TOLERABILITY; EPILEPTIC STATE; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; NEUROSURGERY; NEUROTOXICITY; PRIORITY JOURNAL; PRURITUS; REVIEW; SOFT TISSUE INJURY;

EID: 0029911956     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajhp/53.22.2707     Document Type: Review

References (53)

1. Boucher BA, Bombassaro AM, Rasmussen SN et al. Phenytoin prodrug 3-phosphoryloxymethyl phenytoin (ACC-9653): pharmacokinetics in patients following iv and im administration. J Pharm Sci. 1989; 78:929-32.
2. Browne TR, Kugler AR, Eldon MA. Pharmacology and pharmacokinetics of fosphenytoin. Neurology. 1996; 46(suppl 1):S3-7.
3. Cloyd J. Pharmacologic considerations of fosphenytoin therapy. P&T. 1996; 21(5, suppl):13S-20S.
4. Leppik IE, Boucher BA, Wilder BJ et al. Pharmacokinetics and safety of a phenytoin prodrug given iv or im in patients. Neurology. 1990; 40(3, part 1):456-60.
5. Knapp LE, Kugler AR, Eldon MA. Fosphenytoin: pharmacokinetics and administration. Emerg Med. 1996; 28(suppl):9-16.
6. Sloan EP. Emergency department seizure treatment. P&T. 1996; 21(5S):24S-29S.
7. Andrews CO, Turnbull TL, Paloucek FP et al. Safety and pharmacokinetics of fosphenytoin following intravenous loading dose administration. Phamacotherapy. 1994; 14(3):367. Abstract.
8. Cerebyx package insert. Morris Plains, NJ: Parke-Davis; 1996.
9. Ramsay RE, DeToledo J. Intravenous administration of fosphenytoin: options for the management of seizures. Neurology. 1996; 46(suppl 1):S17-9.
10. Sloan EP. Emergency department seizure treatment with fosphenytoin. Emerg Med. 1996; 28(suppl):17-21.
11. Hussey EK, Dukes GE, Messenheimer JA et al. Evaluation of the pharmacokinetic interaction between diazepam and ACC-9653 (a phenytoin prodrug) in healthy male volunteers. Pharm Res. 1990; 7:1172-6.
12. Lai CM, Moore P, Quon CY. Binding of fosphenytoin, phosphate ester prodrug of phenytoin, to human serum proteins and competitive binding with carbamazepine, diazepam, phenobarbital, phenylbutazone, phenytoin, valproic acid or warfarin. Res Commun Mol Pathol Pharmacol. 1995; 88(1):51-62.
13. Gerber N, Mays DC, Donn KH et al. Safety, tolerance and pharmacokinetics of intravenous doses of the phosphate ester of 3-hydroxymethyl-5,5-diphenylhydantoin: a new prodrug of phenytoin. J Clin Pharmacol. 1988; 28:1023-32.
14. Varia SA, Schuller S, Sloan KB et al. Phenytoin prodrugs. 3. Water-soluble prodrugs for oral and/or parenteral use. J Pharm Sci. 1984; 73:1068-73.
15. Howlett CT, Mathias R, Friess S. Quantitative risk approaches for formaldehyde. Exp Pathol. 1989; 37:119-27.
16. Huff JS. The challenge of managing patients with seizures. Emerg Med. 1996; 28(suppl):2-8.
17. Leppik IE. Current management of status epilepticus. P&T. 1996; 21(5S):6S-12S.
18. Fischer PA. Nursing perspectives in the use of fosphenytoin. P&T. 1996; 21(5S):30S-32S.
19. Runge JW, Allen FH. Emergency treatment of status epilepticus. Neurology. 1996; 46(suppl 1):S20-3.
20. Leppik IE, Boucher R, Wilder BJ et al. Phenytoin prodrug: preclinical and clinical studies. Epilepsia. 1989; 30(suppl 2):S22-6.
21. DeToledo J, Ramsay RE. IM administration of fosphenytoin. Emerg Med. 1996; 28(suppl):26-32.
22. Uthman BM, Wilder BJ, Ramsay RE. Intramuscular use of fosphenytoin: an overview. Neurology. 1996; 46(suppl 1):S24-8.
23. Wilder BJ, Slater J, Malone J et al. Parenteral loading and maintenance phenytoin with fosphenytoin, a phenytoin prodrug. Epilepsia. 1993; 34(suppl 2):27. Abstract.
24. Dilantin package insert. Morris Plains, NJ: Parke-Davis; 1994 Sep.
25. Cloyd JC, Bosch DE, Sawchuk RJ. Concentration-time profile of phenytoin after admixture with small volumes of intravenous fluids. Am J Hosp Pharm. 1978; 35:45-8.
26. Salem RB, Yost RL, Torosian G et al. Investigation of the crystallization of phenytoin in normal saline. Drug Intell Clin Pharm. 1980; 14:605-8.
27. MacDonald MG, Getson PR, Glasgow AM et al. Propylene glycol: increased incidence of seizures in low birth weight infants. Pediatrics. 1987; 79:622-5.
28. Kirman CS. Cardiac effects of diphenylhydantoin, isoniazid, and propylene glycol. Am Heart J. 1976; 92:409-10.
29. Louis S, Kutt H, McDowell F et al. The cardiocirculatory changes caused by intravenous Dilantin and its solvent. Am Heart J. 1967; 74:523-9.
30. Ramsay RE. Pharmacokinetics and clinical use of parenteral phenytoin, phenobarbital, and paraldehyde. Epilepsia. 1989; 30(suppl 2):S1-3.
31. Wade A, Weller PJ, eds. Handbook of pharmaceutical excipients. 2nd ed. Washington, DC: American Pharmaceutical Association; 1994.
32. Peris J, Cunningham CL. Dissociation of tolerance to the hypothermic and tachycardic effects of ethanol. Pharmacol Biochem Behav. 1985; 22:973-8.
33. Gupta PK, Patel JP, Hahn KR. Evaluation of pain and irritation following local administration of parenteral formulations using the rat paw lick model. J Pharm Sci Technol. 1994; 48:159-66.
34. Cranford RD, Leppik IE, Patrick B et al. Intravenous phenytoin: clinical and pharmacokinetic aspects. Neurology. 1978; 28:874-80.
35. Salem RB, Wilder BJ, Yost RL et al. Rapid infusion of phenytoin sodium loading doses. Am J Hosp Pharm. 1981; 38:354-7.
36. York RC, Coleridge ST. Cardiopulmonary arrest following intravenous phenytoin loading. J Emerg Med. 1988; 6:255-9.
37. Uthman BM, Wilder BJ. Emergency management of seizures: an overview. Epilepsia. 1989; 30(suppl 2):S33-7.
38. Watson C. Status epilepticus. Clinical features, pathophysiology, and treatment. West J Med. 1991; 155:626-31.
39. Jamerson BD, Dukes GE, Brouwer KLR et al. Venous irritation related to intravenous administration of phenytoin versus fosphenytoin. Pharmacotherapy. 1994; 14(1):47-52.
40. Hayes AG, Chesney TM. Necrosis of the hand following extravasation of intravenously administered phenytoin. J Am Acad Dermatol. 1993; 28(2, part 2):360-3.
41. Kilarski DJ, Buchanan C, Behren LV. Soft tissue damage associated with intravenous phenytoin. N Engl J Med. 1984; 311:1186-7.
42. Rao VK, Feldman PD, Dibbell DG. Extravasation injury to the hand by intravenous phenytoin. Report of three cases. J Neurosurg. 1988; 68:967-9.
43. MacCara ME. Extravasation: a hazard of intravenous therapy. Drug Intell Clin Pharm. 1983; 17:713-7.
44. Kasdan ML, June LA. Extravasation of phenytoin and diazepam requiring surgical debridement and skingrafting. Orthopedics. 1993; 16:1355-7.
45. Earnest MP, Marx JA, Drury LR. Complications of intravenous phenytoin for acute treatment of seizures. Recommendations for usage. JAMA. 1983; 249:762-5.
46. Hanna DR. Purple glove syndrome: a complication of intravenous phenytoin. J Neurosci Nurs. 1992; 24:340-5.
47. Reeme PD, Day DL. Phenytoin injection precautions. Clin Pharm. 1985; 4:618-20.
48. Comer JB. Extravasation from intravenous phenytoin. Am J Intraven Ther Clin Nutr. 1984; 11(Jan):23-9.
49. Spengler RF, Arrowsmith JB, Kilarski DJ et al. Severe soft-tissue injury following intravenous infusion of phenytoin. Arch Intern Med. 1988; 148:1329-33.
50. Hagan HJ, Hastings H. Extravasation of phenytoin in the hand. J Hand Surg. 1988; 13A:942-3.
51. Wilder BJ, Campbell K, Uthman BM et al. Safety, efficacy and pharmacokinetics of fosphenytoin, a phenytoin prodrug. Epilepsia. 1992; 33(suppl 3):117. Abstract.
52. Baron B, Hankin S, Knapp L. Incidence of complications with intravenous administration of fosphenytoin (Cerebyx) compared with Dilantin. Neurology. 1995; 45(suppl 4):A248. Abstract.
53. Donn KH, Drissel DA, Quon CY. Systemic availability and pharmacokinetics of phenytoin after intramuscular ACC-9653, a phenytoin prodrug. Epilepsia. 1987; 28(5):577-8. Abstract.